Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease

Patients with multiple myeloma, an incurable malignancy of plasma cells, frequently develop osteolytic bone lesions that severely impact quality of life and clinical outcomes. Eliglustat, a U.S. Food and Drug Administration-approved glucosylceramide synthase inhibitor, reduced osteoclast-driven bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Leng, Houfu, Zhang, Hanlin, Li, Linsen, Zhang, Shuhao, Wang, Yanping, Chavda, Selina J., Galas-Filipowicz, Daria, Lou, Hantao, Ersek, Adel, Morris, Emma V., Sezgin, Erdinc, Lee, Yi-Hsuan, Li, Yunsen, Lechuga-Vieco, Ana Victoria, Tian, Mei, Mi, Jian-Qing, Yong, Kwee, Zhong, Qing, Edwards, Claire M., Simon, Anna Katharina, Horwood, Nicole J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780346/
https://www.ncbi.nlm.nih.gov/pubmed/36550101
http://dx.doi.org/10.1038/s41467-022-35358-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780346/
https://www.ncbi.nlm.nih.gov/pubmed/36550101
http://dx.doi.org/10.1038/s41467-022-35358-3

Ejemplares similares